AVAL vs BRK-B

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 0/9, indicating severe deterioration in fundamental performance. Despite strong recent price momentum and solid earnings growth, the company exhibits alarming profitability distortions—operating and gross margins are 0.00%, while the Price/Book ratio of 0.01 suggests either a deep-value opportunity or potential accounting irregularities. Revenue and earnings growth are impressive, but inconsistent earnings surprises and a lack of transparency in balance sheet metrics (missing debt, cash, and Altman Z-Score) undermine confidence. The stock trades above the conservative Graham Number of $80.35, but this appears to be a data error given the current price of $4.68, suggesting possible misreporting or unit discrepancy.

The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.